Truist Financial Corp Acquires 884 Shares of Encompass Health Co. (NYSE:EHC)

Truist Financial Corp increased its holdings in Encompass Health Co. (NYSE:EHC) by 11.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,684 shares of the company’s stock after buying an additional 884 shares during the period. Truist Financial Corp’s holdings in Encompass Health were worth $802,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the business. CIBC Asset Management Inc increased its position in shares of Encompass Health by 3.5% during the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock worth $286,000 after purchasing an additional 100 shares in the last quarter. Miracle Mile Advisors LLC increased its position in shares of Encompass Health by 3.0% during the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock worth $354,000 after purchasing an additional 112 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Encompass Health by 87.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after purchasing an additional 137 shares in the last quarter. Verdence Capital Advisors LLC increased its position in shares of Encompass Health by 4.6% during the third quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company’s stock worth $355,000 after purchasing an additional 160 shares in the last quarter. Finally, V Square Quantitative Management LLC increased its position in shares of Encompass Health by 43.8% during the fourth quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock worth $54,000 after purchasing an additional 177 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Price Performance

NYSE:EHC opened at $100.11 on Friday. Encompass Health Co. has a one year low of $73.68 and a one year high of $104.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The firm has a market cap of $10.09 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 2.31 and a beta of 0.90. The firm’s fifty day moving average is $96.42 and its two-hundred day moving average is $96.36.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Research analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 17th. Stockholders of record on Tuesday, April 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Tuesday, April 1st. Encompass Health’s payout ratio is currently 15.25%.

Insider Transactions at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares of the company’s stock, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 2.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on EHC shares. Royal Bank of Canada reissued an “outperform” rating and issued a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. Barclays upped their target price on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. KeyCorp upped their target price on Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Finally, StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.